Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01042847 · ClinicalTrials.gov registry record
How Our Immune System Can Help Fight Cancer
A clinical trial of Ovarian Cancer, sponsored by Winthrop University Hospital.
- Completed
- Registry status
- 169
- Enrollment target
- 1
- Study location
NCT01042847 is a study of Ovarian Cancer that has completed, run by Winthrop University Hospital. The registered enrollment target is 169 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01042847, a study of Ovarian Cancer, has completed, sponsored by Winthrop University Hospital.
- COMPLETED
- Registry status
- 169 participants
- Enrollment target
- 1
- Study location
Study Summary
There is growing evidence that our immune system can help fight cancer. This has stimulated interest in the development and application of tumor vaccines for several human solid tumors, including epithelial ovarian cancer (EOC). A major obstacle to the development of these vaccines is that there are specialty cells called regulatory T cells that prevent the immune system from attacking all of our organs. These regulatory T cells also prevent our immune system for attacking cancer cells. Indoleamine 2,3-dioxygenase (IDO), an enzyme that degrades an essential amino acid tryptophan that is necessary for T cells to multiply, however regulatory T cells are less susceptible to low levels of tryptophan, and can still multiply. This allows cancer growth and progression. This may be explained by genetic polymorphisms (changes) in the IDO gene, which may alter its function. Five of these changes in the IDO gene have been described. In this research project, we are asking if you would donate a small piece of your tumor and ascites to see if we can examine your IDO gene in the tumor cells and see if any of these gene changes are present. We hope that this will help us understand how the immune system works in EOC. We hypothesize that genetic polymorphisms within the IDO gene alter its enzymatic activity and affect the outcome of ovarian cancer patients. These findings have the potential to translate into a method for predicting successful immunotherapy.
Conditions Studied
Study Locations (1)
New York
- Winthrop-University Hospital - Mineola
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2010-01 |
| Est. Completion | 2015-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01042847
The ClinicalTrials.gov registry entry for NCT01042847 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 169 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (77% lower). The listed sponsor is Winthrop University Hospital, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT01042847 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01042847 about?
NCT01042847 is a clinical study titled "How Our Immune System Can Help Fight Cancer". There is growing evidence that our immune system can help fight cancer. This has stimulated interest in the development and application of tumor vaccines for several human solid tumors, including epithelial ovarian cancer (EOC). A major obstacle to the development of these vaccines is that there are...
What is the current status of trial NCT01042847?
This trial is currently completed. The enrollment target is 169 participants. The study started on 2010-01. Estimated completion is 2015-02.
What conditions does trial NCT01042847 study?
This clinical trial studies the following conditions: Ovarian Cancer.
Who is sponsoring clinical trial NCT01042847?
This trial is sponsored by Winthrop University Hospital, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01042847 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer
RECRUITING
-
The Better, Harder, Faster, Stronger Study
RECRUITING
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.